Global X Management Co. LLC Purchases 3,875 Shares of Hologic, Inc. (HOLX)

Global X Management Co. LLC boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 47.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 11,962 shares of the medical equipment provider’s stock after buying an additional 3,875 shares during the period. Global X Management Co. LLC’s holdings in Hologic were worth $543,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the stock. TrimTabs Asset Management LLC raised its stake in shares of Hologic by 88.8% in the first quarter. TrimTabs Asset Management LLC now owns 2,993 shares of the medical equipment provider’s stock worth $127,000 after buying an additional 1,408 shares in the last quarter. Advisor Partners LLC purchased a new stake in shares of Hologic during the first quarter worth about $201,000. Miles Capital Inc. purchased a new stake in shares of Hologic during the first quarter worth about $206,000. Beck Mack & Oliver LLC purchased a new stake in shares of Hologic during the second quarter worth about $209,000. Finally, Stratos Wealth Partners LTD. purchased a new stake in shares of Hologic during the first quarter worth about $210,000. 94.43% of the stock is currently owned by institutional investors and hedge funds.

Hologic, Inc. (NASDAQ:HOLX) opened at 38.21 on Thursday. The company has a market capitalization of $10.72 billion, a P/E ratio of 14.23 and a beta of 0.90. The stock’s 50 day moving average price is $43.08 and its 200 day moving average price is $42.88. Hologic, Inc. has a 52 week low of $35.15 and a 52 week high of $46.80.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. The company had revenue of $806.10 million during the quarter, compared to the consensus estimate of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. Hologic’s revenue was up 12.4% on a year-over-year basis. During the same period last year, the business posted $0.51 earnings per share. Analysts anticipate that Hologic, Inc. will post $2.01 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This story was posted by [[site]] and is owned by of [[site]]. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at [[permalink]].

HOLX has been the topic of a number of recent research reports. Piper Jaffray Companies reissued a “buy” rating and issued a $51.00 target price on shares of Hologic in a research report on Friday, July 14th. Stifel Nicolaus reissued a “buy” rating on shares of Hologic in a research report on Friday, July 14th. Needham & Company LLC reissued a “buy” rating on shares of Hologic in a research report on Tuesday, August 1st. BidaskClub lowered Hologic from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Finally, BTIG Research reissued a “buy” rating and issued a $47.00 target price on shares of Hologic in a research report on Sunday, May 14th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $48.64.

In other Hologic news, VP Karleen Marie Oberton sold 4,704 shares of the stock in a transaction on Monday, July 17th. The stock was sold at an average price of $45.19, for a total transaction of $212,573.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Elaine Ullian sold 8,938 shares of the stock in a transaction on Friday, June 2nd. The shares were sold at an average price of $43.99, for a total value of $393,182.62. Following the transaction, the director now directly owns 23,810 shares of the company’s stock, valued at $1,047,401.90. The disclosure for this sale can be found here. Insiders have sold 51,551 shares of company stock valued at $2,244,458 over the last ninety days. 0.79% of the stock is currently owned by company insiders.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).